Thomas Eigentler

20.1k total citations · 2 hit papers
264 papers, 9.2k citations indexed

About

Thomas Eigentler is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Thomas Eigentler has authored 264 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Oncology, 99 papers in Molecular Biology and 69 papers in Immunology. Recurrent topics in Thomas Eigentler's work include Cutaneous Melanoma Detection and Management (136 papers), Melanoma and MAPK Pathways (82 papers) and Cancer Immunotherapy and Biomarkers (66 papers). Thomas Eigentler is often cited by papers focused on Cutaneous Melanoma Detection and Management (136 papers), Melanoma and MAPK Pathways (82 papers) and Cancer Immunotherapy and Biomarkers (66 papers). Thomas Eigentler collaborates with scholars based in Germany, United States and Australia. Thomas Eigentler's co-authors include Claus Garbe, Ulrike Leiter, Benjamin Weide, Friedegund Meier, Ralf Gutzmer, Axel Hauschild, Peter Radny, Helmut Breuninger, Annette Pflugfelder and Andrea Forschner and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas Eigentler

253 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidemiology of Skin Cancer

2014 446 citations Ulrike Leiter, Thomas Eigentler et al. profile →
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

2020 442 citations Ralf Gutzmer, Thomas Eigentler et al. profile →

Peers

Countries citing papers authored by Thomas Eigentler

Since Specialization

Citations

This map shows the geographic impact of Thomas Eigentler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Eigentler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Eigentler more than expected).

Fields of papers citing papers by Thomas Eigentler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Eigentler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Eigentler. The network helps show where Thomas Eigentler may publish in the future.

Co-authorship network of co-authors of Thomas Eigentler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Eigentler. A scholar is included among the top collaborators of Thomas Eigentler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Eigentler. Thomas Eigentler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients 2025 ·European Journal of Cancer ·Georg Lodde, Ulrike Leiter, Anja Gesierich, Thomas Eigentler, (unknown), Claudia Pföhler, Thilo Gambichler, Rudolf Herbst, Friedegund Meier, Jessica C. Hassel, Frank Meiß, Peter Mohr, Patrick Terheyden, Georgios Nikolakis, Markus Hecht, Andreas Stang, (unknown), (unknown), Selma Ugurel, Jürgen C. Becker	1
2	How to treat primary cutaneous B cell lymphoma – Results from a monocentric cohort study on 98 patients 2025 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·(unknown), (unknown), Franz J. Hilke, Rose K. C. Moritz, Thomas Eigentler, Max Schlaak, Gábor Dobos	1
3	Initial Experience with Transarterial Chemoembolization in Metastatic Cutaneous Melanoma Patients with Hepatic Progression on Immune Checkpoint Inhibitors 2025 ·CardioVascular and Interventional Radiology ·Timo Alexander Auer, (unknown), Gábor Dobos, Lynn Jeanette Savic, Florian Nima Fleckenstein, Thomas Eigentler, Federico Collettini	0
4	Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial 2025 ·British Journal of Dermatology ·Jürgen C. Becker, Anja Gesierich, Ulrike Leiter, Lisa Zimmer, Jessica C. Hassel, (unknown), Mirjana Ziemer, Michael Fluck, (unknown), (unknown), Bastian Schilling, Thomas Eigentler, Elisabeth Livingstone, Selma Ugurel, (unknown), Christine Windemuth-Kieselbach, Ralf Gutzmer	0
5	Improving assessment of lesions in longitudinal CT scans: a bi-institutional reader study on an AI-assisted registration and volumetric segmentation workflow 2024 ·International Journal of Computer Assisted Radiology and Surgery ·Alessa Hering, Max Westphal, (unknown), Haidara Almansour, Michael Maurer, Benjamin Geisler, (unknown), Thomas Eigentler, (unknown), Nikolas Leßmann, Sergios Gatidis, Horst K. Hahn, Konstantin Nikolaou, Ahmed E. Othman, Jan Hendrik Moltz, (unknown)	6
6	Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? 2024 ·Cancers ·(unknown), (unknown), Alessa Hering, (unknown), Konstantin Nikolaou, Sergios Gatidis, Thomas Eigentler, Teresa Amaral, Jan Hendrik Moltz, Ahmed E. Othman	1
7	Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: A rare but fatal condition 2024 ·Pediatric Blood & Cancer ·Michael Abele, Stephan Forchhammer, Thomas Eigentler, (unknown), (unknown), (unknown), Thomas Lehrnbecher, Wolfgang Behnisch, Andreas H. Groll, (unknown), Benedikt Bernbeck, Ines B. Brecht, Dominik T. Schneider	2
8	Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition 2023 ·Cancers ·Jessica C. Hassel, Lisa Zimmer, (unknown), Thomas Eigentler, Friedegund Meier, Peter Mohr, Tobias Pukrop, Alexander Roesch, Dirk Vordermark, Christina Wendl, Ralf Gutzmer	6
9	In vivo imaging of CD8⁺ T cells in metastatic cancer patients: first clinical experience with simultaneous [⁸⁹Zr]Zr-Df-IAB22M2C PET/MRI 2023 ·Theranostics ·Johannes Schwenck, Dominik Sonanini, (unknown), Walter Ehrlichmann, (unknown), Gerald Reischl, (unknown), Ian A. Wilson, Ron Korn, Irene González-Menéndez, Leticia Quintanilla-Martı́nez, Ferdinand Seith, Andrea Forschner, Thomas Eigentler, Lars Zender, Martin Röcken, Bernd J. Pichler, Lukas Flatz, Manfred Kneilling, Christian la Fougère	10
10	Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia 2023 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), Ulrike Leiter, Claus Garbe, (unknown), (unknown), Thomas Eigentler, (unknown), Hans‐Martin Häfner, Saskia Maria Schnabl	2
11	Development of an Image Analysis-Based Prognosis Score Using Google’s Teachable Machine in Melanoma 2022 ·Cancers ·Stephan Forchhammer, (unknown), Gisela Metzler, Claus Garbe, Thomas Eigentler	11
12	TELEDerm: Implementing store-and-forward teledermatology consultations in general practice: Results of a cluster randomized trial 2022 ·Journal of Telemedicine and Telecare ·(unknown), (unknown), (unknown), Christian Thies, Leonie Sundmacher, Thomas Eigentler, Peter Martus, (unknown), (unknown)	3
13	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry 2021 ·Cancers ·Lina María Serna-Higuita, Teresa Amaral, Andrea Forschner, Ulrike Leiter, Lukas Flatz, (unknown), Ioannis Thomas, Claus Garbe, Thomas Eigentler, Peter Martus	16
14	Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry 2020 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), Teresa Amaral, Ulrike Keim, Ulrike Leiter, Andrea Forschner, Thomas Eigentler, Claus Garbe	16
15	Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients 2020 ·Cancer Immunology Immunotherapy ·Wolfgang Thaiss, Sergios Gatidis, Tina Sartorius, Jürgen Machann, Andreas Peter, Thomas Eigentler, Konstantin Nikolaou, Bernd J. Pichler, Manfred Kneilling	6
16	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 2019 ·Cancer Immunology Immunotherapy ·Benjamin Weide, Thomas Eigentler, Chiara Catania, Paolo A. Ascierto, Stefano Cascinu, Jürgen C. Becker, Axel Hauschild, Antonella Romanini, Riccardo Danielli, Reinhard Dummer, Uwe Trefzer, Giuliano Elia, Dario Neri, Claus Garbe	41
17	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses 2014 ·Cancer Immunology Research ·Benjamin Weide, Thomas Eigentler, Annette Pflugfelder, Henning Zelba, Alexander Martens, Graham Pawelec, Leonardo Giovannoni, Pier Adelchi Ruffini, Giuliano Elia, Dario Neri, Ralf Gutzmer, Jürgen C. Becker, Claus Garbe	77
18	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma 2014 ·Clinical Cancer Research ·Henning Zelba, Benjamin Weide, Alexander Martens, Evelyna Derhovanessian, Jithendra Kini Bailur, Christina Kyzirakos, Annette Pflugfelder, Thomas Eigentler, Anna Maria Di Giacomo, Michele Maio, Erik H.J.G. Aarntzen, I. Jolanda M. de Vries, Antje Sucker, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec	35
19	Proliferative Activity, Chromosomal Aberrations, and Tumor-Specific Mutations in the Differential Diagnosis between Blue Nevi and Melanoma 2012 ·American Journal Of Pathology ·Laura Held, Thomas Eigentler, Gisela Metzler, Ulrike Leiter, Jane L. Messina, L. Frank Glass, Claus Garbe, Jürgen Bauer	20
20	A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma 2011 ·Clinical Cancer Research ·Thomas Eigentler, Benjamin Weide, Filippo de Braud, Gianluca Spitaleri, Antonella Romanini, Annette Pflugfelder, Reinerio González‐Iglesias, Annaelisa Tasciotti, Leonardo Giovannoni, Kathrin Schwager, Valeria Lovato, Manuela Kaspar, Eveline Trachsel, Hans D. Menssen, Dario Neri, Claus Garbe	125

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact